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Carboxypeptidase A1 has been the subject of extensive
research in the last 30 y and is one of the most widely studied
zinc metalloenzymes. However, the three-dimensional struc-
ture of the human form of the enzyme is not yet available. This
report describes the three-dimensional structure of human
carboxypeptidase A1 (hCPA1) derived from crystals that
belong to the tetragonal space group P43212 and diffract to
1.6 A˚ resolution. A description of the ternary complex
hCPA1–Zn2+–poly(acrylic acid) is included as a model of the
interaction of mucoadhesive polymers with proteases in the
gastrointestinal tract. The direct mode of interaction between
poly(acrylic acid) and the active site of the target protease was
confirmed by in vitro inhibition assays. The structure was
further analyzed in silico through the optimal docking-area
method. The characterization of binding sites on the surface of
hCPA1 and a comparison with other available carboxypepti-
dase structures provided further insights into the formation of
multiprotein complexes and the activation mechanisms of
carboxypeptidase zymogens. The high-resolution structure of
hCPA1 provides an excellent template for the modelling of
physiologically relevant carboxypeptidases and could also
contribute to the design of specific agents for biomedical
purposes.
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1. Introduction
Metallocarboxypeptidases (MCPs) are Zn2+-dependent exo-
proteases of widespread distribution which are present in
almost every tissue or fluid examined in mammals and
perform a wide variety of physiological functions (Vendrell et
al., 2004). The protein-degrading activity of CPs requires tight
levels of control, involving their synthesis as inactive precursor
proteins (proenzymes or zymogens), their release into sepa-
rate compartments and the expression of endogenous CP
inhibitors, amongst other strategies.
Based on their primary and tertiary structure, the most
thoroughly studied CPs of the M14 family can be divided into
subfamilies A/B and N/E, which differ in their domain
distribution and the architecture of the loops surrounding the
active site (Wei et al., 2002). Further, the mature enzymes that
catalyze the removal of C-terminal amino acids from proteins
and/or peptides can be roughly classified into two groups: the
forms that preferentially hydrolyze the peptide bonds before
C-terminal aliphatic and aromatic residues (various CPA
forms) and those that are specific for basic residues (such as
CPB, CPN, CPM, CPU/TAFI etc.).
A battery of pancreatic enzymes catalyze the degradation of
the protein content of the diet into free amino acids in the
gastrointestinal tract and their activity may impair the bio-
availability of therapeutic peptides and proteins (Lee et al.,
2000). An increasingly explored area in the pharmaceutical
field is the development of strategies to enhance the absorp-
tion of protein and peptide medications. In this context, the
co-administration of bioadhesive polymers is used to prolong
the contact time of many drugs with body tissue, improving
their performance (Lee et al., 2000). In addition to their
mucoadhesive properties and their permeation-enhancing
effects, certain polymers are able to inhibit the protease
activities in the intestine. Among them, the mucoadhesive
polymer poly(acrylic acid) (PAA), used as a co-administered
product, has been shown to inhibit CPA activity in the
gastrointestinal tract (Luessen et al., 1996).
The enzyme mechanism of CPs has essentially been eluci-
dated (Kim & Lipscomb, 1990; Christianson & Lipscomb,
1986) and three-dimensional structures are available for many
different CPs (Vendrell et al., 2004). However, although full
structural details of human pancreatic CPA2 and CPB are
known (PDB codes 1aye and 1kwm, respectively), the three-
dimensional structure of human CPA1 is not yet available. In
addition to being considered the reference or ‘canonical’ form
for functional and mechanistic studies of proteases, mature
hCPA1 and its proregion have been linked to human diseases
and are considered to be serum markers for the diagnosis of
pancreatic cancer (Bar-Or et al., 2006; Shamamian et al., 2006;
Matsugi et al., 2007). The availability of three-dimensional
structures of peptidases related to disease may be beneficial to
the drug-discovery process (Mittl & Grutter, 2006). For
instance, full details of the active site of hCPA1 and of its
differences compared with that of hCPA2 or hCPB might aid
in the design of new prodrugs for cancer therapy (Smith et al.,
1997).
The binding of ligands to CPs has been the subject of
extensive research, with special emphasis on inhibitors of
either natural or synthetic origin (Kim, 2004; Christianson &
Lipscomb, 1989). In the case of pancreatic CPs, the concept of
ligand binding can be extended to the interaction with their
own activation domain and with accompanying proteases in
quaternary complexes (Pascual et al., 1989). Modern tech-
nologies such as the optimal docking-area (ODA) method are
valuable tools for the identification of exosites or potential
ligand-binding sites on the surface of the protein (Fernandez-
Recio et al., 2005). The continuous surface patches with
optimal docking desolvation energy defined by ODA could be
regarded as docking sites that might be exploited in the
identification of atypical CP inhibitors, i.e. compounds that do
not coordinate to the metal ion. The recent successful appli-
cation of the ODA method to the CP M14 family based on
complexes of known three-dimensional structure (Fernandez
et al., 2007) permits its extrapolation to newly released
structures.
A description of the newly determined three-dimensional
structure of human CPA1 is presented here, together with a
study of potential binding sites for multiprotein complex
formation and a description of the mode of binding of PAA to
the active site of the enzyme in what, to our knowledge, is the
first example of a complex between a mucoadhesive polymer
and a target digestive protease of the human gastrointestinal
tract.
2. Materials and methods
2.1. Protein preparation and crystallization
Human pancreatic pro-CPA1 (hPCPA1) was overexpressed
in the supernatant medium of the yeast Pichia pastoris
heterologous system following established procedures (Bayes
et al., 2003). Briefly, after hydrophobic interaction chromato-
graphy on a butyl-Toyopearl column followed by preparative
chromatography on an anion-exchange TSK-DEAE column
(60 min gradient from 0 to 0.15M ammonium acetate in
20 mM Tris pH 7.0 at a flow rate of 4 ml min1), recombinant
hPCPA1 was activated with trypsin at a 40:1(w:w) ratio and
the prodomain was removed by gel filtration. After concen-
tration, the purified protein (1 ml) dissolved at 6 mg ml1 in
5 mM Tris–HCl, 50 mM NaCl pH 7.5 was mixed in a 1:1 ratio
with the crystallization solutions. Crystals grew in 22%(w/v)
PAA 5100, 0.1M HEPES, 0.02M magnesium chloride pH 7.5
crystallization buffer using a sitting-drop vapour-diffusion
setup at 293 K.
2.2. Data collection and processing
For data collection, crystals were soaked in a cryobuffer
containing 30%(v/v) glycerol before freezing in a nitrogen
stream at 100 K (Oxford Cryosystems Cryostream). High-
resolution data to 1.6 A˚ were collected on the DESY BW6
beamline (Deutsches Elektronen Synchrotron, Hamburg,
Germany) at a wavelength of 1.050 A˚. Indexing and integra-
tion of the diffraction data was carried out with DENZO
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Table 1
X-ray data collection and processing.
Values in parentheses are for the last resolution shell.
Space group P43212
Unit-cell parameters (A˚, ) a = 129.6, b = 129.6, c = 90.9,
 = 90.0,  = 90.0,  = 90.0
Molecules per ASU 2
Resolution (A˚) 20.0–1.60 (1.68–1.60)
Reflections measured/unique 521057/101271
I/(I) 33.5 (5.0)
Rmerge† 0.054 (0.439)
Completeness (%) 98.8 (83.1)
Reflections used for refinement (total/test set) 100653/2012
R factor‡ (%)/Rfree§ (%) 17.8/19.2
No. of non-H atoms 5018
No. of residues 616
No. of solvent molecules 779
No of ligands (Zn2+/PAA/HEPES) 2/2/6
R.m.s.d. bond lengths (A˚) 0.007
R.m.s.d. bond angles () 1.4
R.m.s.d. bonded B factors (A˚2) 0.94
Average B factor for protein atoms (A˚2) 20.0
Average B factor for PAA (A˚2) 23.0
Average B factor for metal ions (A˚2) 15.4
Ramachandran core conformations (%) 87.3
Additionally allowed conformations (%) 12.5
Disallowed conformations (%) 0.2
† Rmerge =
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ. ‡ R factor =
P
hkl

jFobsj 
jFcalcj

=
P
hkl jFobsj. § Rfree was calculated omitting 2% of the observed reflections from
refinement and R-factor calculation.
(Otwinowski & Minor, 1997). The data were merged, scaled
and truncated using programs supported by CCP4 (Colla-
borative Computational Project, Number 4, 1994). Table 1
provides a summary of the data collection and processing.
2.3. Structure determination and processing
The structure of hCPA1 was solved by molecular replace-
ment using the AMoRe program suite (Navaza, 1994) and a
bovine CPA1 search model (PDB code 5cpa; Rees et al., 1983)
which consisted of the residues that were conserved in both
enzymes, with all other residues mutated to alanine. After
rigid-body fitting, the best solution reached a correlation
coefficient and R factor of 36.1% and 46.1%, respectively, for
data in the resolution range 15.0–3.5 A˚. Model building was
performed on a Silicon Graphics Indigo 2 workstation using
the program MAIN (Turk, 1992). Positional and individual
temperature-factor refinement was carried out with the
program CNS (Bru¨nger et al., 1998) until convergence without
imposing noncrystallographic symmetry constraints and the
final model yielded final R and Rfree values of 17.8% and
19.2%, respectively. The two hCPA1 molecules present in the
crystal asymmetric unit are structurally equivalent, with an
r.m.s.d. of 0.23 A˚ for C atoms. Therefore, only molecule A is
considered in the description of the structure. The hCPA1
chain encompasses protein residues Ala1–Pro308 and a Zn2+
ion which was identified and refined with full occupancy.
Additional electron density near the active site was inter-
preted as a PAA molecule and three HEPES molecules were
found on the surface. During the final steps of refinement,
alternative conformations were identified and built for a few
side chains.
The Ramachandran plot calculated for the final hCPA1
model with the program PROCHECK (Laskowski et al., 1993)
shows that 87.3% of the residues are in the most favoured
regions of the ’,  plane, 12.5% of residues are in additionally
allowed regions and only one amino-acid residue appears in a
disallowed region. Only residual electron density was detected
beyond the last observable methylene of PAA and it was not
possible to construct a reliable model accounting for a puta-
tively more extended polymer chain.
2.4. Inhibition assays
Poly(acrylic acid, sodium salt) 5100, the substrate N-[3-(2-
furyl)acryloyl]-l-phenylalanyl-l-phenylalanine (FAPP) and
bovine pancreatic CPA1 were from Sigma; the substrate N-(4-
methoxyphenylazoformyl)-l-phenylalanine (AAFP) was ob-
tained from Bachem. To calculate the Ki values for PAA
against hCPA1, measurements of enzymatic activity were
carried out at an enzyme concentration of 5 nM and variable
concentrations of ligand (100 nM to 100 mM) and FAPP
substrate (25–250 mM) in 50 mM Tris, 0.5M NaCl pH 7.5 at
room temperature in 1 ml cuvettes. Changes in absorbance
were followed at 330 nm. Assays using the bovine form of the
enzyme (bCPA1) were also carried out under the same buffer
and temperature conditions but using the substrate AAFP and
following the absorbance changes at 350 nm. In this case, a
continuous photometric assay was used at an enzyme con-
centration of 50 nM, a substrate concentration fixed at its Km
value of 0.11 mM (Mock et al., 1996) and ligand concentrations
that spanned from 10 nM to 1 mM. The measurements were
carried out in a CARY 100 Bio Spectrophotometer (Varian).
Data were analyzed with the GraphPad Prism 5.0 package. A
nonlinear regression fitting to a single-site ligand competitive
model yielded kinetic parameters with excellent agreement
with the experimental data.
2.5. Calculation of ODA patches
To identify continuous surface patches with optimal
desolvation energy, we followed the procedure established in a
previous publication (Fernandez et al., 2007). Briefly, a
number of starting points were defined around the protein
using the centre of coordinates of each residue side chain. The
docking surface energy of the different-sized patches was then
calculated at each point as the sum of the solvation energy
contribution of the atoms that lie within a sphere of radius d
(d = 1, 2, . . . , 20 A˚) from the starting point. Among all surface
patches generated in this way, that with the lowest energy
value is called an ODA and its optimal energy value is
assigned to that point and subsequently to the residue from
which that point was generated. ODAs were considered only
for residues at the surface of the protein, i.e. when the relative
solvent-accessible surface area (SASA) of the residue is
greater than 0.25. An ODA was considered to be significant
when its optimal docking energy value was <42 kJ mol1.
Finally, the ODA energy values per residue were used to
define regions of the protein surface (ODA patches) that are
likely to be involved in protein–protein binding.
3. Results and discussion
3.1. Overall structure of human CPA1 and comparison with
other CP structures
The crystals belonged to the tetragonal space group P43212,
with unit-cell parameters a = b = 129.6, c = 90.9 A˚, and
contained two molecules per asymmetric unit. Two other
entries in the PDB belong to the same space group and
correspond to MCPs bound to protein inhibitors (PDB codes
1zli and 2abz). This paper reports the determination of a new
structure of a CP bound to a synthetic compound that behaves
as an inhibitor of the protease. The statistics for the structure
at the final 1.6 A˚ resolution are listed in Table 1.
Like its other nonhuman homologues (Vendrell et al., 2004),
the tertiary fold of hCPA1 corresponds to the -hydrolase
fold and is formed by a central mixed parallel/antiparallel
eight-stranded -sheet with a 120 twist between the first and
the last strand, over which eight -helices pack on both sides
to form a globular molecule (Fig. 1). Superimposition of the
hCPA1 structure onto that of its bovine and porcine ortho-
logues (PDB codes 5cpa and 1pca, respectively) gave r.m.s.d.
values of 0.4 A˚ for 308 C atoms in both cases. Of the human
CP forms, hCPA2 is the enzyme that bears the higher degree
of similarity to hCPA1 (Fig. 2) and pairwise comparison of the
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three-dimensional structures gave an r.m.s.d. value of 0.6 A˚ for
301 equivalent C atoms. The specificity pocket of both
enzymes is lined by residues that are at equivalent positions in
the three-dimensional structure. Gly253, Ser254 and Ala268 in
hCPA2 substitute for larger or more polar residues in the A1
form (Garcı´a-Sa´ez et al., 1997), defining a wider pocket for
hCPA2 that is able to accommodate bulkier residues and that
also has a stronger hydrophobic character.
The amino-acid residue at position 255 appears to be the
main determinant of specificity for the A/B subfamily of
MCPs. As in all mammalian CPAs, residue 255 is an isoleucine
in hCPA1, while hCPB (PDB code 1kwm) has an aspartic acid
at this position, accounting for the specificity of B-type
enzymes for C-terminal basic residues. The surface loops of
hCPB also show some differences compared with the
equivalent loops in hCPA1, which, together with the different
orientation of the N-termini, gives an r.m.s.d. value of 1.4 A˚
for 301 C atoms.
Most members of the N/E subfamily of CPs function in the
processing of biologically active peptides, whereas many of
those from the A/B subfamily act in the digestion of dietary
protein. These functional differences are also reflected in the
three-dimensional structures. The structures of hCPA1 and the
second catalytic domain of duck CPD (dCPD-II; PDB code
1qmu; a representative member of the N/E subfamily) can be
superimposed with an r.m.s.d. of 1.5 A˚ for 239 topologically
research papers
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Figure 2
Structure-based sequence alignment of hCPA1 and other CPs: h, human; b, bovine; p, porcine; Ha,Helicoverpa armigera; d, duck; CPT, carboxypeptidase
from Thermoactinomyces vulgaris. The alignment was made with ClustalW (http://www.ebi.ac.uk/clustalw) and manually refined to account for
experimental information. Conserved residues for catalysis are boxed in grey. The regular secondary-structure elements (helices and strands) indicated
below the sequences correspond to the hCPA1 structure. Between the sequences and the symbols for secondary structure, grey lined boxes indicate
regions of topological divergence between hCPA1 and dCPDII, the only representative of the N/E subfamily of CPs. The sequence of dCPDII is
truncated at its C-terminal end, showing only the residues corresponding to its CP moiety.
Figure 1
Cartoon representation of hCPA1. The PAA molecule is shown as a
yellow stick model, the Zn atom is represented as a green sphere and the
three Zn2+-coordinating residues at the active site (His196, Glu72 and
His69, from left to right in this view) are shown as green sticks. This figure
was generated with PyMOL (http://www.pymol.org).
equivalent C atoms, whereas the r.m.s.d. value rises to 6.7 A˚
when all C atoms are considered. The most important
differences between the catalytic subdomains can be observed
in the chain segments that form the funnel-like access to the
active-site cleft. As can be seen in Fig. 2, most disagreements
in the alignment come from the entry corresponding to dCPD-
II. The insertions and deletions shape an entrance to the active
site of dCPD-II that is clearly distinguishable from that in
hCPA1 and other A/B enzymes (Gomis-Ruth et al., 1999). All
these differences, which are also observed in comparisons with
the recently determined structures of hCPM (Reverter et al.,
2004) and hCPN (Keil et al., 2007), suggest that members of
the N/E subfamily have a distinct selectivity towards peptide
substrates.
3.2. The active site
The active site is located in a cavity formed by parallel
strands of the internal -sheet at the switch point between
strands 3 and 5, two helices and a non-regular extension that
partially covers it. It has been reported that the active site of
CPAs is found in two different conformations depending on
the binding of substrates, substrate analogues or inhibitors
(Rees & Lipscomb, 1981; a sketch of the two conformations is
shown in Supplementary Fig. 11). In the presence of substrates,
inhibitors or anions that occupy the active site, Tyr248 rotates
about its 1 torsion angle in a movement that spans about
12 A˚ and fixes it in the ‘down’ position, closing the access to
the active site. Tyr248 has been found in the ‘down’ position in
the PCI–bCPA1 complex (Rees & Lipscomb, 1982; PDB code
4cpa), porcine PCPA1 (Guasch et al., 1992; PDB code 1pca),
the LCI–hCPA2 complex (Reverter et al., 2000; PDB code
1dtd) and now in hCPA1.
A strong density at the active site was interpreted as a PAA
molecule, a ligand present in the crystallization solution. As
discussed in x3.3, the binding of a PAA molecule to the active
site delineates the positions of the S10 and S1 subsites. Similar
interactions involving the two main residues of the S1 site,
Arg127 and Glu270, were also observed in the LCI–hCPA2
complex. PAA was found to interact with most of the active-
site residues and correspondingly some residues are found in
the conformation induced by substrate or inhibitor binding.
3.3. The interaction of the PAA molecule in the active site of
human CPA1
The coordination of Zn2+ in the active site is conserved
compared with other MCPs. The first coordination shell of the
Zn atom usually consists of four protein atoms, Glu72 O"1,
Glu72 O"2, His69 N1 and His196 N1, and one water molecule.
In the present structure (Fig. 3) the catalytic water molecule
has been displaced by the PAA molecule and substituted by
the O1 and O2 atoms which interact with Zn2+. A water
molecule 3.8 A˚ away from the zinc interacts with Arg71 N1
(2.9 A˚), Arg127 N2 (3.0 A˚) and with the O1 group of the
PAA molecule (2.6 A˚).
PAA exploits the flexibility of its carbon chain to accom-
modate its functional groups so as to satisfy all possible
interactions within the active site, resulting in its binding to
hCPA1 being mediated by the four carboxylate groups (Table
2). As shown in the complementary view of PAA binding
presented in Fig. 4, starting from the far-right carboxylate
group (the -carboxylate), the dihedral angles are gauche/
gauche/trans/trans/trans/trans, suggesting that the carbon-
chain structure is twisted so as to allow the - and -carbox-
ylates to interact with Zn2+ and Arg145. The mode of action of
the two central - and -carboxylates, the first of which
coordinates bidentately with the Zn2+ ion and the other
establishing a salt bridge with Arg145, resembles that of
typical CP inhibitors such as l-benzylsuccinic acid (PDB code
1cbx) and the pseudo-substrate ZAAP(O)F (PDB code 6cpa;
Kim & Lipscomb, 1990). A superimposition of the latter
structure with that presented here shows that the -carbox-
ylate is located exactly over the POO— moiety that coordi-
nates the Zn2+. The -carboxylate is oriented towards Arg71
in a fashion similar to the carbonyl O atom of the first Ala
residue in ZAAP(O)F.
The most striking difference between PAA and the typical
phenylalanine-based inhibitors is the presence of the
-carboxylate at the hydrophobic binding pocket of hCPA1.
Fig. 4 shows that it occupies a space where the benzyl ring of a
phenylalanine-based ligand is commonly found. Probably to
satisfy a hydrogen-bonding interaction with the polar ligand,
Thr268 orients its side chain so as to contact PAA via its OH
group. This feature results in the Thr268 1 dihedral angle
being trans (1 = 177.1), in clear contrast to other CP
structures, in which the most common rotamer conformation is
gauche (60). A further stabilization of the Thr268 confor-
mation may be provided by the hydrogen bond between atom
O1 and the main-chain carbonyl O atom of Ser194. Thr268 is
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Table 2
Intermolecular contacts between the PAA molecule and the enzyme
moiety.
Enzyme atom PAA atom Distance (A˚)
Zn2+ O1 2.5
Zn2+ O2 2.1
His69 N1 O2 3.0
Arg71 N1 O1 3.3
Glu72 O"1 O1 3.2
Glu72 O"1 O2 3.1
Arg127 N1 O1 3.2
Arg127 N1 O2 3.2
Arg127 N2 O2 2.8
Arg127 N2 O1 3.3
Asn144 N2 O1 3.0
Asn144 N2 O2 2.9
Arg145 N2 O1 2.8
Arg145 N1 O2 2.8
Tyr248 O O1 2.6
Thr268 O1 O2 2.6
Glu270 O"1 O2 3.1
Glu270 O"1 O1 2.7
Glu270 O"2 O1 3.1
1 Supplementary material has been deposited in the IUCr electronic archive
(Reference: HV5106). Services for accessing this material are described at the
back of the journal.
considered to be an important determinant of specificity in
CPs; its uncommon rotamer conformation might create a
different binding pocket for ligands, as has been reported in a
previous drug-design investigation (Smith et al., 1997).
Other investigations have dealt with the inhibitory and thus
drug-protective effects of some polymers, such as poly-
acrylates, against a number of digestive proteases including
trypsin, -chymotrypsin, CPA, CPB and
cytosolic leucine aminopeptidase (Luessen
et al., 1995, 1996). It has been argued that
protease inhibition mainly originates from
the sequestration of active-site Zn2+ or Ca2+
ions, thus rendering the enzymes inactive.
However, some metalloenzymes require
higher concentrations of polymer to achieve
an inhibitory effect (this is the case for
cytosolic leucine aminopeptidase, a Zn2+-
dependent metalloenzyme) or appear not to
be inhibited at all by polymers (as in the
case of microsomal leucine aminopeptidase)
and consequently alternative modes of
interaction cannot be ruled out (Luessen et
al., 1995, 1996).
The structure reported here reveals a
direct interaction between a mucoadhesive
polymer and a digestive protease and
suggests that the mode of action of
mucoadhesive polymers, apart from a putative metal-
depriving effect, could also involve occupation of the protease
substrate-binding site. Those polymers that combine delivery
capabilities with protease-inhibitory effects might be exploited
in a structure-based drug-design strategy aimed at the devel-
opment of novel and specific excipients to improve the bio-
availability of non-invasively administered peptide drugs
(Bernkop-Schnurch & Kast, 2001).
In light of the structural evidence, hCPA1–PAA crystals
were picked up from the drops, carefully washed and dissolved
in a substrate-containing solution. No carboxypeptidase
activity was detected by enzymatic measurements. Subse-
quently, in vitro inhibition assays were performed with a fresh
sample of hCPA1 using various enzyme:PAA ratios at
different substrate concentrations. The profile of the double-
reciprocal representation shows that addition of PAA affects
Km and not Vmax and thus corresponds to competitive inhi-
bition with aKi value of 8.7 mM (see Supplementary Fig. 2). To
investigate whether PAA is also able to inhibit hCPA1
orthologues, we also calculated the Ki value for bCPA1 using a
continuous assay method (Bieth, 1995), which rendered a
similar Ki value of 8 mM after fitting to a competitive-
inhibition model. For comparison, the benchmark inhibitor
dl-benzylsuccinic acid has a Ki value of about 1.0 mM against
the same target. These observations are consistent with the
structural data and indicate that PAA behaves as an inhibitor
and interacts directly with the protease.
3.4. Binding sites and complex formation of hCPA1 as studied
by the optimal docking-area method
The ODA (optimal docking-area) method is an efficient
algorithm that identifies areas on the surface of a protein that
have a higher probability of being involved in protein–protein
interactions (Fernandez-Recio et al., 2005). We have applied
ODA analysis to the structure of hCPA1 and compared the
results with those obtained from a set of known three-
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Figure 4
Close-up view of the active site of hCPA1 in complex with PAA (yellow
carbon chain) superimposed on bCPA1 in complex with the phosphonate
inhibitor ZAAP(O)F (PDB code 6cpa). For the latter structure only the
inhibitor is shown, with a light blue carbon chain and the P atom in
orange. Some residues involved in catalysis and substrate binding in
hCPA1 are shown as green stick models. Try248 adopts the ‘down’
conformation (see Supplementary Fig. 1). Other residues commented
upon in the text describing this figure are not shown for clarity. The Zn2+
atom is represented as a green sphere. The carboxylate groups in the PAA
moiety are labelled as they are named in the text. The hydrogen bond
between the -carboxylate and Thr268 is marked with a dashed line. This
figure was prepared with the program PyMOL (http://www.pymol.org).
Figure 3
Stereo plot of active-site residues of hCPA1 in complex with PAA (yellow carbon chain). The
figure shows an OMITelectron-density map of bound PAA contoured at the 1 level. The Zn2+
atom is represented by a green sphere. Residues in the zinc-coordination sphere, as well as the
catalytically relevant Glu270, are shown. This figure was rendered with BobScript (Esnouf,
1997).
dimensional structures of the M14 family of CPs that were the
subject of a recent structural and functional characterization
of binding sites using this method (Fernandez et al., 2007). In
the mentioned study it was found that although the set of CP-
enzyme domains were structurally very similar, the protein–
protein docking surfaces of different subclasses differed
substantially and could be distinguished based on analysis of
ODA residues over the surface of the protein.
Alignment of the sequences of hCPA1 and bCPA1 indicates
that regardless of the conservation of individual residues, the
grouping of ODA residues in the cata-
lytic domains is very similar in both
proteins (see Supplementary Fig. 3). All
segments of clustered ODA residues in
the catalytic domains correspond to
areas in which interactions with either
the activation domain or protein inhi-
bitors are known to take place
(Fernandez et al., 2007). A surface
representation indicates that the distri-
bution of ODA patches is very similar in
the two proteins (Fig. 5).
Pancreatic CPs are synthesized as
zymogens (procarboxypeptidases,
PCPs) that occur as binary or ternary
complexes with other proproteinase
subunits. These associations differ
between organisms; for instance,
ternary complexes have only been
observed in ruminants, while binary
complexes have a wider occurrence.
Human PCPA1 is known to occur as a
binary complex with proproteinase E
(PPE), the zymogen of a digestive
serine proteinase, whereas bPCPA1
occurs both as a binary complex similar
to the human form and a ternary
complex in which the additional subunit
is chymotrypsinogen C (CTGC; see
Aviles et al., 1993). Fig. 6 compares the
structures of a virtual hPCPA1 zymogen
and the bovine ternary zymogen
complex (PDB code 1pyt). For the
construction of the virtual hCPA1
zymogen, the structures of the enzyme
regions of hCPA1 and pPCPA1, the
sequentially closer orthologue, were
superimposed and the coordinates for
the porcine enzyme moiety were
subsequently eliminated from the
figure, rendering a virtual chimera built
up of the enzyme moiety of hCPA1 and
the pro-region of pPCPA1. Most
protein–protein interactions in the
ternary complex are mediated via the
prodomain of the CP, which sustains
almost all the interactions to dock both
proproteinases; the contribution of the
CP moiety is only marginal. A visual
observation of the ODA-coloured
structures indicates that the constructed
hPCPA1 displays a PPE-binding surface
research papers
790 Pallare`s et al.  Carboxypeptidase A1 Acta Cryst. (2008). D64, 784–791
Figure 6
Representation of the surfaces of ODA patches for (a) a virtual hPCPA1 (constructed from hCPA1
and the pro-region of pPCPA1) and (b) the natural bovine ternary complex built up of bPCPA1,
PPE (green backbone representation) and CTGC (gold backbone). The yellow arrow indicates the
location of the centre of the ODA-rich region between residues 90 and 99 in bCPA1. The view must
be approximately rotated 180 vertically and 90 downwards horizontally to correspond with the
orientation in Fig. 5. Other details are as in Fig. 5. This figure was prepared with the program
PyMOL (http://www.pymol.org).
Figure 5
Representation of the surfaces of ODA patches for (a) bCPA1 and (b) hCPA1. The view points the
active-site cleft towards the reader. A yellow arrow marks the entrance to the active site, where a
green sphere depicts the Zn2+ ion. The colour ramp ranges from red (ODA energy value
<42 kJ mol1) to blue (ODA energy value = 0.0). The experimental ligand interface is indicated
with a green line for bCPA1. This figure was prepared with the program PyMOL (http://
www.pymol.org) and the colour ramp was generated using an in-house script.
with ODA energy patches extensive enough to accommodate
a PPE subunit, as could be expected from the natural occur-
rence of the porcine zymogen as a binary complex with PPE
(Ventura et al., 1997). On the other side, bPCPA1 is richer in
ODA residues at the surface at which CTGC is accom-
modated, where the residues contained in the long -helix
(Val82–Arg99) connecting the activation and the catalytic
domains display the highest ODA energy values (residues 90–
99) and are of particular importance in bPCPA1–CTGC
binding. It is conceivable that as the long -helix contains the
cleavable arginine residue, species-dependent binding of pro-
proteinases to this region and the subsequent formation of
oligomeric zymogen complexes modulates the kinetics of
active-enzyme generation (Gomis-Ruth et al., 1998). The
computation of ODA energy patches for the known structures
of CPs and PCPs is in agreement with the observed occurrence
of complexes which are responsible for the differences in
activation behaviour between ruminant and mammal PCPs.
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